<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521219</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-HNP050</org_study_id>
    <nct_id>NCT03521219</nct_id>
  </id_info>
  <brief_title>A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma</brief_title>
  <official_title>Single Arm, Exploratory and Open Clinical Trial of Second-line Therapy With Apatinib Mesylate in Advanced Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Zhengzhou University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The propose of this study is to confirm safety and efficacy of Apatinib monotherapy in
      patients with advanced cholangiocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>1 month</time_frame>
    <description>the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>24 month</time_frame>
    <description>Time from start of treatment until the first documented event of symptomatic progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>1 month, 3 month, 6 month</time_frame>
    <description>Proportion of patients with reduction in tumor burden of a predefined amount</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>36 month</time_frame>
    <description>from start of treatment to death from any cause, or last known date of survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages 18-65 years;

          2. Eastern Cooperative Oncology Group performance score (ECOG): 0-2;

          3. Estimated survival time &gt; 3 months;

          4. Patients with recurrent or metastatic cholangiocarcinoma with histologic or
             cytological diagnosis;

          5. Previous first-line GP programmes failed, or were not able to withstand first-line
             treatment;

          6. At least one measurable lesion [spiral CT scan ≥ 10 mm (CT scan thickness not greater
             than 5mm)], Measurable lesions were not treated with radiotherapy or other topical
             treatments unless progress was achieved after treatment was completed (RECIST version
             1.1);

          7. Adequate hepatic, renal, heart, and hematologic functions: ANC ≥ 1.5×109/L, PLT ≥
             75×109/L, HB ≥ 8 g/dL,ALB ≥2.8g/dL，TBIL ≤ 3×ULN, ALT or AST≤ 2.5×ULN (or ≤ 5×ULN in
             patients with liver metastases), Cr clearance ≥ 50 mL/min;Thyroid function is normal；

          8. No serious history of drug allergy；

          9. Subjects volunteered for the study. Sign informed consent, good compliance, with
             follow-up.

        Exclusion Criteria:

          1. Patients have received targeted therapy；

          2. Patients with contraindications (active bleeding, ulcers, intestinal perforation,
             intestinal obstruction, within 30 days after major surgery, uncontrolled high blood
             pressure medication, III-IV level cardiac insufficiency, severe liver and kidney
             dysfunction)；

          3. Coagulation dysfunction (INR&gt; 1.5, PT&gt; ULN +4s or APTT&gt; 1.5 ULN), with bleeding
             tendency or ongoing thrombolysis or anti-blood coagulation treatment；

          4. Urine routine showed that urine protein ≥++ or the urine protein in 24 hours＞1.0 g；

          5. Pregnant or lactating women；

          6. History of other malignancy within 5 years except for effectively treated skin basal
             cell carcinoma, cutaneous squamous cell carcinoma and / or effectively excised
             orthotopic cervical and / or breast cancer;

          7. The researchers judged other conditions that might affect clinical research and the
             outcome of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei He</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei He</last_name>
    <phone>18638553286</phone>
    <email>hewei726@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei He</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2018</study_first_submitted>
  <study_first_submitted_qc>May 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Wei He</investigator_full_name>
    <investigator_title>Deputy Chief Physician of Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

